2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Proheparin-binding EGF-like growth factor, Heparin-binding EGF-like growth factor (HB-EGF; HBEGF), Diphtheria toxin receptor (DT-R) |
| Accession | Q99075 |
| Amino Acid Sequence | Asp63-Leu148 |
| Expression System | E.coli |
| Molecular Weight | 14-17 kDa (Reducing) |
| Purity | >95% by SDS-PAGE. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Cytokine Growth Factor Rev. 2000 Dec;11(4):335-44. |
Background
HB-EGF is a member of the epidermal growth factor (EGF) family, encoded by the HBEGF gene on human chromosome 5q23. It is synthesized as a type I transmembrane precursor (pro-HB-EGF) of approximately 208 amino acids, which undergoes proteolytic cleavage by ADAM10 and ADAM17 metalloproteinases to release a soluble 87-amino acid mature form (sHB-EGF). Notably, the remaining C-terminal fragment can translocate to the nucleus and regulate transcription, representing a novel signaling mechanism distinct from canonical EGFR activation.
HB-EGF uniquely contains a heparin-binding domain that mediates high-affinity interactions with heparan sulfate proteoglycans (HSPGs), enabling localization to cell-cell contact sites and modulating its bioavailability. This juxtacrine signaling property distinguishes HB-EGF from other EGF family members.
Picture
Picture
SDS-PAGE
ELISA
Immobilized HB-EGF, Human (Cat. No. UA040500) at 5.0μg/mL (100μL/well) can bind EGFR Fc Chimera, Human (Cat. No. UA010174) with EC50 of 1.45-2.27 ng/mL.
